2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates CancerNetwork® Inaugural Face-Off Contemporary Concepts in Hematologic Oncology Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer Real-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC with Uncommon EGFR Mutations

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC with Uncommon EGFR Mutations

Clinical

View More Acute Myeloid Leukemia Brain Cancer Breast Cancer Colorectal Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Hematology Leukemia Lung Cancer Lymphoma Pediatric Cancers Skin Cancer

Acute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer

News

Clinical Topics Integrative Care Global Bulletin All News Approval Alert

Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert

Media

2 Minute Drill Around the Practice Awareness Month Between the Lines Clinical Consult Expert Interviews Face Off Medical World News Morning Rounds OncView Podcasts Readout 360 Year in Review

2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsMorning RoundsOncViewPodcastsReadout 360Year in Review

Conferences

Publications

All Journals For Authors Tumor Board

All JournalsFor AuthorsTumor Board

Contemporary Concepts Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored

Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored

eNewsletter Print Subscription

eNewsletterPrint Subscription

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Spotlight

2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Real-World Evidence in NSCLC Guides Clinical Decisions
Targeting NSCLC with Uncommon EGFR Mutations

ClinicalSee All >

Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Andrew Dmytrijuk, MD | Authors

Eltrombopag for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

December 01, 2009

On November 20, 2008, the US Food and Drug Administration (FDA) granted accelerated approval for eltrombopag (Promacta Tablets, GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy.